Goldman Sachs Resumes KeyCorp (KEY) at Neutral
Get Alerts KEY Hot Sheet
Price: $22.72 -1.69%
Rating Summary:
22 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 24
Rating Summary:
22 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 24
Join SI Premium – FREE
Goldman Sachs resumes coverage on KeyCorp (NYSE: KEY) with a Neutral. PT $8.75.
The firm said the high-cost CD re-pricing opportunity is a significant NIM tailwind for KeyCorp. With the highest-cost CD book of the regionals they coverage, and approximately $2.5 billion of "high-cost" pre-2009 CDs set to mature in 2012 the CD re-pricing opportunity for KEY is very significant, especially over 2H12-2013. Goldman thinks the company can grow its NIM by 6 bp in 2012. That said, low leverage of capital and deposits is a longer-term drag on returns.
For an analyst ratings summary and ratings history on KeyCorp click here. For more ratings news on KeyCorp click here.
Shares of KeyCorp closed at $8.02 yesterday.
The firm said the high-cost CD re-pricing opportunity is a significant NIM tailwind for KeyCorp. With the highest-cost CD book of the regionals they coverage, and approximately $2.5 billion of "high-cost" pre-2009 CDs set to mature in 2012 the CD re-pricing opportunity for KEY is very significant, especially over 2H12-2013. Goldman thinks the company can grow its NIM by 6 bp in 2012. That said, low leverage of capital and deposits is a longer-term drag on returns.
For an analyst ratings summary and ratings history on KeyCorp click here. For more ratings news on KeyCorp click here.
Shares of KeyCorp closed at $8.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyCorp (KEY) PT Raised to $25 at RBC Capital
- Cantor Fitzgerald Starts Dyne Therapeutics (DYN) at Overweight
- KeyCorp (KEY) PT Raised to $26 at Keefe, Bruyette & Woods; 'Growth Strengthening'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share